Does Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Stimulation Reduce Alcohol Intake in Patients With Alcohol Dependence: Study Protocol of a Randomised, Double-Blinded, Placebo-Controlled Clinical Trial

BMJ Open - United Kingdom
doi 10.1136/bmjopen-2017-019562
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

BMJ

Related search

Glucagon-Like Peptide-1 Receptor (GLP1R; GLP-1R)

Science-Business eXchange
2009English

Cardiovascular Effects of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists

Cardiovascular Diabetology
Internal MedicineCardiologyEndocrinologyCardiovascular MedicineMetabolismDiabetes
2014English

Double-Blind, Randomized Placebo-Controlled Clinical Trial of Benfotiamine for Severe Alcohol Dependence

Drug and Alcohol Dependence
PsychiatryToxicologyMental HealthPharmacology
2013English

The Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exendin-4 Reduces Cocaine Self-Administration in Mice

Physiology and Behavior
PhilosophyBehavioral NeuroscienceExperimentalCognitive Psychology
2015English

A Mechanism for Agonist Activation of the Glucagon-Like Peptide-1 (GLP-1) Receptor Through Modelling & Molecular Dynamics

Biochemical and Biophysical Research Communications
BiochemistryCell BiologyMolecular BiologyBiophysics
2018English

Glucagon-Like Peptide-1 Receptor (GLP-1R) Signaling Ameliorates Dysfunctional Immunity in COPD Patients

International Journal of COPD
EnvironmentalPublic HealthHealth PolicyMedicinePulmonaryRespiratory MedicineOccupational Health
2018English

Dose-Dependent Effects of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes Inadequately Controlled With Metformin: A Randomized, Double-Blind, Placebo-Controlled Trial

Diabetic Medicine
Internal MedicineEndocrinologyMetabolismDiabetes
2010English

Effects of Subcutaneous Glucagon-Like Peptide 1 (GLP-1 [7-36 Amide]) in Patients With NIDDM

Diabetologia
Internal MedicineEndocrinologyMetabolismDiabetes
1996English

Protocol for Meal-Time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C Trial): A Randomised, Double-Blinded, Placebo-Controlled Trial

BMJ Open
Medicine
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy